PMV Pharma Q2 net loss $35.7M; cash $277.4M; PC14586 combo with KEYTRUDA planned

PMV Pharmaceuticals, Inc.

2023-Q2 EPS reported -$0.79

Net loss for H1 2022: $35.7M vs $24.5M YoY; cash, cash equivalents and marketable securities $277.4M as of June 30, 2022.
R&D expenses $23.3M in H1 2022 vs $15.2M in H1 2021, driven by PC14586 clinical trial costs.
Initial PC14586 Phase 1 data presented at ASCO; entered clinical collaboration with Merck for PC14586 + KEYTRUDA combo trial starting Q4 2022.
Appointed Marc Fellous, M.D. as VP, Clinical Development and Medical Affairs; previous experience at Bayer and Roche.
Net cash used in operations $31.7M in H1 2022 vs $22.1M in H1 2021; cash burn increased 43%.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.